EnglishУкраїнська
  • Main
  • Useful links
  • Information for Contributors
  • About
  • Editorial board

  • Article
    Vakhnenko A.V.

    MODERN APPROACHES TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH CONCOMITANT CHRONIC HEART FAILURE


    About the author: Vakhnenko A.V.
    Heading LITERATURE REVIEWS
    Type of article Review article
    Annotation The foreign and domestic literature and the results of different studies are summarized in the review artricle, to consider the possibility of pharmacotherapy and synthesis of existing information about the treatment of patients with COPD and concomitant cardiac insufficiency. There are a lot of different studies which are already published demonstrating the existence of a direct association between COPD and cardiovascular clinical outcomes. The treatment strategy in patients with COPD and concomitant cardiac insufficiency should be aware of the risk of the total prescribed drug groups. Some drugs are traditionally prescribed in patients with CCI (ACE inhibitors, β-blockers, statins) have a negative effect on the course of COPD, and glukocorticosteroids, without which it is difficult to cure COPD, may have adverse effects on the cardiovascular system. The difficulties of drug therapy are in mutually exclusive approaches to the treatment of COPD and concomitant cardiovascular disease. The concept of co-treatment of respiratory and cardiovascular disease supplemented and extended these last few years. The discovery of new mechanisms of action have already known drugs, revised ratio of "risk-benefit" in their nomination in this group of patients. But despite that management of these patients remains a challenge for physicians and requires a well-considered assignments. The goal of treatment is control over the prevention of disease progression, mortality reduction, increased exercise tolerance, improving the quality of life of the patient.
    Tags chronic obstructive pulmonary disease, chronic cardiac insufficiency
    Bibliography
    • Айсанов  З.Р. Хронические обструктивные болезни легких. Федеральная программа /  З.Р. Айсанов [и др.] // РМЖ. - 2001. - Т.9. - №1. - С. 23-25.
    • Архипов  В.В. Применение иАПФ при бронхообструктивных заболеваниях: безопасность и нежелательные лекарственные реакции / В.В. Архипов // Качественная Клиническая Практика. - 2003. - №2. - С. 101-107.
    • Дворецкий Л.И. Ведение пожилого больного ХОБЛ / Л.И. Дворецкий // - М.: Литтера, 2005. - 216 с.
    • Козлова Л.И. Функциональное состояние респираторной и сердечно-сосудистой систем больных хронической обструктивной болезнью легких и ишемической болезнью сердца: Автореф. дис. … д-ра мед. наук. - М., 2001.
    • Мареев В.Ю. Перспективы в лечении хронической сердечной недостаточности / В.Ю. Мареев, Ю.Н. Беленков // Сердечная недостаточность. - 2002. - №3. - С. 109-114.
    • Чучалина А.Г.  Хроническая обструктивная болезнь легких. Клинические рекомендации / А.Г. Чучалина // - М.: Атмосфера, 2003. - 168 с.
    • Чазов Е.И. Рациональная фармакотерапия сердечно-сосудистых заболеваний: руководство для практикующих врачей / Е.И. Чазов [и др] // - М.: Литтерра, 2004. - 972 с.
    • Чазов Е.И. Рациональная фармакотерапия сердечно-сосудистых заболеваний: руководство для практикующих врачей / Е.И. Чазов, Ю.Н. Беленков // - М., 2006. - Т.4. - Гл. 1-4,10,14. - С. 31-74, 111-125, 176-187.
    • Шевченко О.П. Статины – ингибиторы ГМГ-КоА-редуктазы / О.П. Шевченко, А.О. Шевченко // - М.: Реафарм, 2003. - 112 с.
    • Buch P. Reduced lung function and risk of atrial fibrillation in the Copenhagen City Heart Study / P. Buch, J. Friberg, H. Scharling [et al.] // Eur. Respir. J. - 2003. - №21(6). - Р. 1012-1016.
    • Briel M. Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials / M. Briel, G.G. Schwartz, P.L. Thompson [et all.]  // JAMA. - 2006. - №295. - Р. 2046-2056.
    • Behar S. Se among 5,839 consecutive patients with acute myocardial infarction: SPRINT Study Group / S. Behar, A. Panosh, H. Reicher-Reiss [et all.] //  Am. J. Med. – 2009. - №93(6). - Р. 637-641.
    • β-Blockers May Reduce Mortality and Risk of Exacerbations in Patients With Chronic Obstructive Pulmonary Disease / Frans H. Rutten [at al.] // Arch Intern Med. - 2010. - 170(10). - Р. 880-887.
    • Celli B.R. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper / B.R. Celli , W. MacNee  // Eur. Respir. J. - 2004. - №23(6). - Р. 932-946.
    • Dankner R. Predictors of cardiac and noncardiac mortality among 14,697 patients with coronary heart disease / R. Dankner, U. Goldbourt, V. Boyko [at al.] // Am. J. Cardiol. - 2003. - №91(2). - Р. 121-127.
    • Frost F.J. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins /  F.J. Frost, H. Petersen, K. Tollestrup [at al.] // Chest. - 2007. - 131(4). - Р. 1006-1012.
    • Hedblad B. Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: main results from the b-blocker cholesterol-lowering asymptomatic plaque study (BCAPS) / B. Hedblad,  J. Wikstrand, L. Jabzon [at al.] // Circulation. - 2001. - №103. - Р. 1721-1726.
    • Huiart L. Low-dose inhaled corticosteroids and the risk of acute myocardial infarction in COPD / P. Ernst, X. Ranouil, S. Suissa [at al.] // Eur. Respir. J. - 2005. - Vol. 25. - P. 634-639.
    • Islamoglu F. Predictors of outcome after coronary artery bypass grafting in patients older than 75 years of age / F. Islamoglu, H. Reyhanoglu, O. Berber  [at al.] // Med. Sci. Monit. - 2003. - №9(8). - CR369-CR376.
    • Luomanmaki K. efficacy and tolrrability of isradipine and metoprolol in treatment of hypertention” the Finnish Isradipin Study in Hypertention (FISH) / K. Luomanmaki, J. Inkovaara, M.  Hartikainen // J. Cardiovasc Pharmacol. - 1992. - №20. - Р. 296-303.
    • Poulsen S.H. Clinical outcome of patients with suspected pulmonary embolism. A follow-up study of 588 consecutive patients / S.H. Poulsen, I. Noer, J.E. Moller  [et al.]  // J. Intern. Med. - 2001. - 250(2). - Р.137-143.
    • Pedersen T.R. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial / T.R. Pedersen, O. Faergeman, J.J. Kastelein [at al.] // JAMA. - 2005. - Vol. 294. - P. 2437-2445.
    • Schalekamp M. Influence of ACE inhibition on pulmonary haemoydynamics and function in patients in whom в-blockers are contraindicated / M. Schalekamp, G. Dietze, L. Bertoli [et al.] // Postgrad Med J. - 1986. - №62. - Р. 47-51.
    • Sin D.D. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease / D.D. Sin, P. Lacy, E. York [et al.] // Am. J. Respir. Crit. Care Med. - 2004. - Vol. 170. - P. 760-765.
    • Sidney S. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program / S. Sidney , M. Sorel, C.P. Jr Quesenberry  [et al.] // Chest. - 2005. -  128(4). - Р. 2068-2075.
    • Truelsen T. Lung function and risk of fatal and non-fatal stroke. The Copenhagen City Heart Study / T. Truelsen, E. Prescott, P. Lange [et al.] // Int. J. Epidemiol. – 2001. - №30(1).  - Р. 145-151.
    • Waagstein F. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy / F. Waagstein, MR. Bristow, K. Swedberg // Lancet. - 1993. - №342. - Р. 1441-1446.
    Publication of the article «World of Medicine and Biology» №3(40) 2 part 2013 year, 070-073 pages, index UDK 616.24-002-08+616.12-008.46